A share price of Agios Pharmaceuticals Inc [AGIO] is currently trading at $32.99, up 10.78%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AGIO shares have gain 23.10% over the last week, with a monthly amount glided 53.37%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 22, February 2024, Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024. In a post published today on Yahoo Finance, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024, at 2:10 p.m. ET.
From an analyst’s perspective:
Previously, Piper Sandler started tracking the stock with Overweight rating on February 03, 2023, and set its price target to $41. On November 17, 2022, upgrade upgraded it’s rating to Neutral and revised its price target to $32 on the stock. SVB Leerink upgraded its rating to a Outperform but stick to its price target of $33 on July 27, 2022. BofA Securities initiated its recommendation with a Buy and recommended $54 as its price target on December 03, 2021. Goldman downgraded its rating to Sell for this stock on July 30, 2021, and downed its price target to $39. In a note dated July 01, 2021, Raymond James initiated an Mkt Perform rating.
Agios Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $19.80 and $30.05. Currently, Wall Street analysts expect the stock to reach $44 within the next 12 months. Agios Pharmaceuticals Inc [NASDAQ: AGIO] shares were valued at $32.99 at the most recent close of the market. An investor can expect a potential return of 33.37% based on the average AGIO price forecast.
Analyzing the AGIO fundamentals
Trailing Twelve Months sales for Agios Pharmaceuticals Inc [NASDAQ:AGIO] were 26.82M which represents 64.80% growth. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 30.60 points at the first support level, and at 28.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 34.64, and for the 2nd resistance point, it is at 36.30.
Agios Pharmaceuticals Inc [AGIO] reported earnings per share of -$1.72 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.65/share, meaning a difference of -$0.07 and a surprise factor of -4.20%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.64 per share as compared to estimates of -$1.7 per share, a difference of $0.06 representing a surprise of 3.50%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Agios Pharmaceuticals Inc [NASDAQ:AGIO] is 12.27. As well, the Quick Ratio is 11.99, while the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 69.12, the price to book ratio is 2.28.
Transactions by insiders
Recent insider trading involved Washburn Theodore James Jr., Principal Accounting Officer, that happened on Feb 20 when 504.0 shares were sold. Chief Medical Officer, Gheuens Sarah completed a deal on Feb 14 to sell 642.0 shares. Meanwhile, Chief Legal Officer Burns James William sold 545.0 shares on Feb 14.
